ReviewReviews in endocrine & metabolic disorders2026
Bone health in diabetes mellitus.
Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bone health depends on a complex interplay between cellular and extracellular components that together preserve skeletal integrity, microarchitecture, and mechanical strength. Disturbance of this balance in a range of pathophysiological states, particularly in diseases such as diabetes mellitus, may substantially impair bone quality, delay fracture healing, and increase fracture risk. This review summarizes the main mechanisms linking diabetes and bone health, with emphasis on advanced glycation, oxidative stress, chronic inflammation, hormonal and osteoimmune dysregulation, microvascular impairment, and altered mesenchymal stem cell fate. We also review bone turnover markers, the skeletal effects of contemporary glucose-lowering therapies, and emerging methodological approaches, including single-cell and spatial transcriptomic analyses. A more integrated understanding of these processes may improve risk stratification, treatment decisions, and prevention of skeletal complications in diabetes.
Indexed as
Identifiers
42853518What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.